Susquehanna Fundamental Investments LLC Makes New $802,000 Investment in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Susquehanna Fundamental Investments LLC bought a new position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 376,661 shares of the company's stock, valued at approximately $802,000. Susquehanna Fundamental Investments LLC owned approximately 0.18% of Allogene Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Syon Capital LLC bought a new stake in Allogene Therapeutics during the fourth quarter valued at $39,000. Hsbc Holdings PLC raised its holdings in Allogene Therapeutics by 32.0% in the fourth quarter. Hsbc Holdings PLC now owns 69,155 shares of the company's stock worth $147,000 after purchasing an additional 16,768 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Allogene Therapeutics by 30.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,561,626 shares of the company's stock worth $7,586,000 after buying an additional 831,146 shares during the last quarter. Gilead Sciences Inc. bought a new stake in shares of Allogene Therapeutics during the fourth quarter valued at approximately $2,464,000. Finally, XTX Topco Ltd bought a new position in Allogene Therapeutics during the fourth quarter valued at approximately $338,000. Institutional investors and hedge funds own 83.63% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on ALLO shares. Royal Bank of Canada reissued an "outperform" rating and set a $10.00 price target on shares of Allogene Therapeutics in a research note on Friday, March 14th. Canaccord Genuity Group reissued a "buy" rating and set a $14.00 price objective on shares of Allogene Therapeutics in a research report on Friday, March 14th. HC Wainwright reduced their price objective on Allogene Therapeutics from $9.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, March 19th. Finally, Citizens Jmp raised Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 price objective on the stock in a research note on Friday, March 14th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $9.29.

Insider Activity at Allogene Therapeutics

In other news, CEO David D. Chang sold 46,668 shares of the stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $1.96, for a total transaction of $91,469.28. Following the sale, the chief executive officer now directly owns 5,276,569 shares of the company's stock, valued at $10,342,075.24. This represents a 0.88 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders have sold 61,757 shares of company stock valued at $115,873. 24.30% of the stock is owned by corporate insiders.

Allogene Therapeutics Stock Performance

Shares of NASDAQ ALLO traded down $0.03 during mid-day trading on Thursday, reaching $1.17. The company had a trading volume of 4,688,430 shares, compared to its average volume of 3,267,136. Allogene Therapeutics, Inc. has a 12-month low of $1.11 and a 12-month high of $3.78. The company has a market capitalization of $255.45 million, a price-to-earnings ratio of -0.75 and a beta of 0.60. The stock has a fifty day moving average of $1.61 and a two-hundred day moving average of $1.99.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.06. Sell-side analysts forecast that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).